Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 70.3% from a year ago

Total equity stood at $238.28M at the end of Q1 FY2026, up 70.3% from a year earlier and up 19.3% from the prior quarter. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • Total equity amounted to 88.6% of total assets at the end of Q1 FY2026, down 6.2 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +70.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$238.28M+19.3% QoQ
Last fiscal yearDec 2025
$199.74M+37.4% YoY
Year agoMar 2025
$139.89M+70.3% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70.3%——
1 year+37.4%——
3-year CAGR+9.7%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
199.74M USD
Year-over-year change
+37.4%
4-year CAGR
+14.4%

Total Equity vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +70.3% is the 2nd highest of 11, against a peer median of -19.2%.
  • Total equity amounts to 88.6% of total assets for ORMP, versus a peer median of 87.3%.
ORMP Competitors
Total Equity for ORMP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORMPOramed Pharmaceuticals Inc.Mar 2026$238.28M USD+70.3%+9.7%88.6%
OVIDOvid Therapeutics Inc.Mar 2026$198.27M USD+234.5%-0.4%87.9%
IMAImageneBio IncMar 2026$123.33M USD+4.3%-3.2%90.2%
STTKShattuck Labs, Inc.Mar 2026$95.84M USD+41.8%-22.4%93.8%
KLRSKalaris Therapeutics IncMar 2026$68.56M USD+7.3%—62.4%
CNTXContext Therapeutics Inc.Mar 2026$52.2M USD-42.6%+20.3%88.7%
COYACoya Therapeutics, Inc.Mar 2026$48.97M USD+46.8%—91.9%
CNTBConnect Biopharma Holdings LimitedDec 2025$41.98M USD-54.5%-35.6%74.9%
IFRXInflaRx N.V.Mar 2026€36.93M EUR-47.6%-22.2%75.5%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
CLNNClene Inc.Mar 2026-$18.81M USD-278.2%—86.8%
Peer median (excluding ORMP) —-19.2%-22.2%87.3%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents77.25M40.46M9.06M54.42M45.95M
Short-term Investments16.9M115.26M152.99M87.51M79.95M
Net Receivables00004.64M
Inventory00000
Other Current Assets1.2M1.39M537K1.29M2.74M
Total Current Assets95.34M157.11M162.58M143.22M133.27M
Property, Plant & Equipment (Net)932K1.81M1.57M1.11M1.34M
Goodwill00000
Intangible Assets00000
Long-term Investments6.69M2.7M56.37M10.91M93.74M
Tax Assets00000
Other Non-current Assets25.04M24K34K34K2.52M
Total Non-current Assets32.66M4.53M57.97M12.06M97.59M
Total Assets128M161.64M220.55M155.28M230.86M
Account Payables2.61M2.18M551K789K443K
Short-term Debt130K247K51.01M00
Tax Payables0003.2M0
Deferred Revenue2.7M1.34M001.35M
Other Current Liabilities(1.37M)(191K)325K1.07M2.37M
Total Current Liabilities6.68M5.75M53.21M5.69M19.09M
Long-term Debt403K647K000
Deferred Tax Liabilities11K11K007.91M
Deferred Revenue (Non-current)4.24M4M4M4M3.27M
Other Non-current Liabilities145K82K102K90K314K
Total Non-current Liabilities4.8M4.74M4.44M4.25M12.03M
Total Liabilities11.48M10.49M57.66M9.93M31.12M
Common Stock424K476K485K480K472K
Retained Earnings(114.85M)(163.08M)(157.56M)(176.62M)(123.44M)
Accumulated OCI00000
Other Stockholders Equity230.2M314.42M000
Minority Interest744K(656K)(928K)(918K)0
Total Equity116.52M151.16M162.89M145.35M199.74M
Total Debt533K894K51.62M372K825K
Net Debt(76.71M)(39.57M)42.57M(54.05M)(45.12M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.